Ayhan Parlar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayhan Parlar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Meral Yüce
SUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye
3 shared publications - Aylin Ozkan
Biotechnology Analytical Development Department of Ilko Argem Biotechnology Center , Teknopark , Istanbul , Turkiye
2 shared publications - Busra Gurel
SUNUM Nanotechnology Research and Application Center, Sabanci University, Istanbul 34956, Turkey
2 shared publications - Duygu Emine Daglikoca
ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey
2 shared publications - Eda Capkin
ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey
2 shared publications - Meltem Corbacioglu Pala
ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey
2 shared publications
Latest Publications
- Open Access
- 28 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (8) , 1571
Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovator. Thus, it is fractionated into acidic, main, and basic isoforms and collected physically by Cation Exchange Chromatography (CEX) for a comprehensive structural and functional analysis. The innovator product, fractionated into the same species and collected by the same method, is used as a reference for comparative analysis. Ultra-Performance Liquid Chromatography (UPLC) ESI-QToF was used to analyze the modifications leading to charge heterogeneities at intact protein and peptide levels. The C-terminal lysine clipping and glycosylation profiles of the samples were monitored by intact mAb analysis. The post-translational modifications, including oxidation, deamidation, and N-terminal pyroglutamic acid formation, were determined by peptide mapping analysis in the selected signal peptides. The relative binding affinities of the fractionated charge isoforms against the antigen, VEGF-A, and the neonatal receptor, FcRn, were revealed by Surface Plasmon Resonance (SPR) studies. The results show that all CEX fractions from the innovator product and the SIMAB054 shared the same structural variants, albeit in different ratios. Common glycoforms and post-translational modifications were the same, but at different percentages for some samples. The dissimilarities were mostly originating from the presence of extra C-term Lysin residues, which are prone to enzymatic degradation in the body, and thus they were previously assessed as clinically irrelevant. Another critical finding was the presence of different glyco proteoforms in different charge species, such as increased galactosylation in the acidic and afucosylation in the basic species. SPR characterization of the isolated charge variants further confirmed that basic species found in the CEX analyses of the biosimilar candidate were also present in the innovator product, although at lower amounts. The charge variants’ in vitro antigen- and neonatal receptor-binding activities varied amongst the samples, which could be further investigated in vivo with a larger sample set to reveal the impact on the pharmacokinetics of drug candidates. Minor structural differences may explain antigen-binding differences in the isolated charge variants, which is a key parameter in a comparability exercise. Consequently, such a biosimilar candidate may not comply with high regulatory standards unless the binding differences observed are justified and demonstrated not to have any clinical impact.
- 28 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (8) , 1571
Open AccessStructural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovator. Thus, it is fractionated into acidic, main, and basic isoforms and collected physically by Cation Exchange Chromatography (CEX) for a comprehensive structural and functional analysis. The innovator product, fractionated into the same species and collected by the same method, is used as a reference for comparative analysis. Ultra-Performance Liquid Chromatography (UPLC) ESI-QToF was used to analyze the modifications leading to charge heterogeneities at intact protein and peptide levels. The C-terminal lysine clipping and glycosylation profiles of the samples were monitored by intact mAb analysis. The post-translational modifications, including oxidation, deamidation, and N-terminal pyroglutamic acid formation, were determined by peptide mapping analysis in the selected signal peptides. The relative binding affinities of the fractionated charge isoforms against the antigen, VEGF-A, and the neonatal receptor, FcRn, were revealed by Surface Plasmon Resonance (SPR) studies. The results show that all CEX fractions from the innovator product and the SIMAB054 shared the same structural variants, albeit in different ratios. Common glycoforms and post-translational modifications were the same, but at different percentages for some samples. The dissimilarities were mostly originating from the presence of extra C-term Lysin residues, which are prone to enzymatic degradation in the body, and thus they were previously assessed as clinically irrelevant. Another critical finding was the presence of different glyco proteoforms in different charge species, such as increased galactosylation in the acidic and afucosylation in the basic species. SPR characterization of the isolated charge variants further confirmed that basic species found in the CEX analyses of the biosimilar candidate were also present in the innovator product, although at lower amounts. The charge variants’ in vitro antigen- and neonatal receptor-binding activities varied amongst the samples, which could be further investigated in vivo with a larger sample set to reveal the impact on the pharmacokinetics of drug candidates. Minor structural differences may explain antigen-binding differences in the isolated charge variants, which is a key parameter in a comparability exercise. Consequently, such a biosimilar candidate may not comply with high regulatory standards unless the binding differences observed are justified and demonstrated not to have any clinical impact.
- Open Access
- 31 May 2022
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 90 (2) , 36
Optimized Methods for Analytical and Functional Comparison of Biosimilar mAb Drugs: A Case Study for Avastin, Mvasi, and Zirabev
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the originators without giving detailed analytical procedures. In the current study, several key methods were optimized and reported for analytical and functional comparison of bevacizumab originators (Avastin, Altuzan) and approved commercial biosimilars (Zirabev and Mvasi). This case study presents a comparative analysis of a set of biosimilars under optimized analytical conditions for the first time in the literature. The chemical structure of all products was analyzed at intact protein and peptide levels by high-resolution mass spectrometry; the major glycoforms and posttranslational modifications, including oxidation, deamidation, N-terminal PyroGlu addition, and C-terminal Lys clipping, were compared. The SPR technique was used to reveal antigen and some receptor binding kinetics of all products, and the ELISA technique was used for C1q binding affinity analysis. Finally, the inhibition performance of the samples was evaluated by an MTS-based proliferation assay in vitro. Major glycoforms were similar, with minor differences among the samples. Posttranslational modifications, except C-terminal Lys, were determined similarly, while unclipped Lys percentage was higher in Zirabev. The binding kinetics for VEGF, FcRn, FcγRIa, and C1q were similar or in the value range of originators. The anti-proliferative effect of Zirabev was slightly higher than the originators and Mvasi. The analysis of biosimilars under the same conditions could provide a new aspect to the literature in terms of the applied analytical techniques. Further studies in this field would be helpful to better understand the inter-comparability of the biosimilars.
- 31 May 2022
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 90 (2) , 36
Open AccessOptimized Methods for Analytical and Functional Comparison of Biosimilar mAb Drugs: A Case Study for Avastin, Mvasi, and Zirabev
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the originators without giving detailed analytical procedures. In the current study, several key methods were optimized and reported for analytical and functional comparison of bevacizumab originators (Avastin, Altuzan) and approved commercial biosimilars (Zirabev and Mvasi). This case study presents a comparative analysis of a set of biosimilars under optimized analytical conditions for the first time in the literature. The chemical structure of all products was analyzed at intact protein and peptide levels by high-resolution mass spectrometry; the major glycoforms and posttranslational modifications, including oxidation, deamidation, N-terminal PyroGlu addition, and C-terminal Lys clipping, were compared. The SPR technique was used to reveal antigen and some receptor binding kinetics of all products, and the ELISA technique was used for C1q binding affinity analysis. Finally, the inhibition performance of the samples was evaluated by an MTS-based proliferation assay in vitro. Major glycoforms were similar, with minor differences among the samples. Posttranslational modifications, except C-terminal Lys, were determined similarly, while unclipped Lys percentage was higher in Zirabev. The binding kinetics for VEGF, FcRn, FcγRIa, and C1q were similar or in the value range of originators. The anti-proliferative effect of Zirabev was slightly higher than the originators and Mvasi. The analysis of biosimilars under the same conditions could provide a new aspect to the literature in terms of the applied analytical techniques. Further studies in this field would be helpful to better understand the inter-comparability of the biosimilars.
- Open Access
Influence of Fluid Properties on Intensity of Hydrodynamic Cavitation and Deactivation of Salmonella typhimurium
In this study, three microfluidic devices with different geometries are fabricated on silicon and are bonded to glass to withstand high-pressure fluid flows in order to observe bacteria deactivation effects of micro cavitating flows. The general geometry of the devices was a micro orifice with macroscopic wall roughness elements. The width of the microchannel and geometry of the roughness elements were varied in the devices. First, the thermophysical property effect (with deionized water and phosphate-buffered saline (PBS)) on flow behavior was revealed. The results showed a better performance of the device in terms of cavitation generation and intensity with PBS due to its higher density, higher saturation vapor pressure, and lower surface tension in comparison with water. Moreover, the second and third microfluidic devices were tested with water and Salmonella typhimurium bacteria suspension in PBS. Accordingly, the presence of the bacteria intensified cavitating flows. As a result, both devices performed better in terms of the intensity of cavitating flow with the presence of bacteria. Finally, the deactivation performance was assessed. A decrease in the bacteria colonies on the agar plate was detected upon the tenth cycle of cavitating flows, while a complete deactivation was achieved after the fifteenth cycle. Thus, the proposed devices can be considered as reliable hydrodynamic cavitation reactors for “water treatment on chip” applications.
Open AccessInfluence of Fluid Properties on Intensity of Hydrodynamic Cavitation and Deactivation of Salmonella typhimurium
In this study, three microfluidic devices with different geometries are fabricated on silicon and are bonded to glass to withstand high-pressure fluid flows in order to observe bacteria deactivation effects of micro cavitating flows. The general geometry of the devices was a micro orifice with macroscopic wall roughness elements. The width of the microchannel and geometry of the roughness elements were varied in the devices. First, the thermophysical property effect (with deionized water and phosphate-buffered saline (PBS)) on flow behavior was revealed. The results showed a better performance of the device in terms of cavitation generation and intensity with PBS due to its higher density, higher saturation vapor pressure, and lower surface tension in comparison with water. Moreover, the second and third microfluidic devices were tested with water and Salmonella typhimurium bacteria suspension in PBS. Accordingly, the presence of the bacteria intensified cavitating flows. As a result, both devices performed better in terms of the intensity of cavitating flow with the presence of bacteria. Finally, the deactivation performance was assessed. A decrease in the bacteria colonies on the agar plate was detected upon the tenth cycle of cavitating flows, while a complete deactivation was achieved after the fifteenth cycle. Thus, the proposed devices can be considered as reliable hydrodynamic cavitation reactors for “water treatment on chip” applications.